The Oxford COVID19 vaccine might be available in India by February 2021 : Adar Poonawalla

Serum Institute of India (SII) CEO Adar Poonawalla has said that the Oxford COVID-19 vaccine might be available in India by February 2021 for the healthcare workers and elderly people.

 The Oxford COVID19 vaccine might be available in India by February 2021 : Adar Poonawalla

Serum Institute of India (SII) CEO Adar Poonawalla has said that the Oxford COVID-19 vaccine might be available in India by February 2021 for the healthcare workers and elderly people. He said that the folk might be inoculated by April. The vaccine are going to be priced a maximum of Rs 1,000.

“If everything goes consistent with plan, January-February 2021 is our deadline for creating the vaccine available to frontline workers and to the overall public by March, April next year,” he said while speaking at the Hindustan Times Leadership Summit (HTLS), 2020 on Thursday. Probably by 2024, he said, every Indian will get vaccinated.

He explained that it'll take two-three years for the whole population to urge inoculated undue to the availability constraints but because "you need the budget, the vaccine, logistics, infrastructure then , people should be willing to require the vaccine". "It are going to be 2024 for everyone , if willing to require a two-dose vaccine, to be vaccinated," Poonawalla said.

Speaking about the vaccine's price, he said that it'll be around USD 5-6 per dose with an MRP of around Rs 1,000 for the 2 doses. He said that the govt are going to be ready to catch on cheaper because it'll procure an outsized volume. "We are still pricing it far cheaper and cheaper than other vaccines we've within the market today," Poonawalla said.

Meanwhile, the SII and Indian Council of Medical Research (ICMR) have announced the completion of enrolment process of 1,600 participants within the phase-III clinical trials for COVID-19 vaccine Covishield within the country. SII and therefore the ICMR are collaborating on the clinical trials of the vaccine within the country. While ICMR has funded the clinical test site fees, SII is taking care of other expenses for the Covishield which is that the India name of the Covid-19 vaccine candidate developed by the University of Oxford and AstraZeneca.Currently, SII and ICMR are conducting phase II/III clinical test of the vaccine at 15 different centres across the country.

Last Updated :